Immunic Inc (IMUX)

Currency in USD
1.080
-0.040(-3.57%)
Closed·
Pre Market
1.100+0.020(+1.85%)
·
IMUX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 9 days
Fair Value
Day's Range
1.0601.180
52 wk Range
0.5612.110
Key Statistics
Prev. Close
1.08
Open
1.14
Day's Range
1.06-1.18
52 wk Range
0.561-2.11
Volume
1.29M
Average Volume (3m)
1.84M
1-Year Change
-25.52%
Book Value / Share
-0.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMUX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.640
Upside
+607.41%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Immunic Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Immunic Inc Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Compare IMUX to Peers and Sector

Metrics to compare
IMUX
Peers
Sector
Relationship
P/E Ratio
−1.1x−5.4x−0.5x
PEG Ratio
−0.020.020.00
Price/Book
−19.6x3.6x2.6x
Price / LTM Sales
-229.7x3.2x
Upside (Analyst Target)
-168.1%41.2%
Fair Value Upside
Unlock7.9%6.2%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.640
(+607.41% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.25 / -0.2225
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMUX Income Statement

People Also Watch

2.000
ONDS
-6.10%
0.055
NCNA
-8.39%
0.1035
OST
-13.89%
6.650
GVH
-7.64%

FAQ

What Stock Exchange Does Immunic Trade On?

Immunic is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Immunic?

The stock symbol for Immunic is "IMUX."

What Is the Immunic Market Cap?

As of today, Immunic market cap is 103.48M.

What Is Immunic's Earnings Per Share (TTM)?

The Immunic EPS (TTM) is -0.95.

When Is the Next Immunic Earnings Date?

Immunic will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is IMUX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Immunic Stock Split?

Immunic has split 1 times.

How Many Employees Does Immunic Have?

Immunic has 90 employees.

What is the current trading status of Immunic (IMUX)?

As of 29 Jul 2025, Immunic (IMUX) is trading at a price of 1.08, with a previous close of 1.08. The stock has fluctuated within a day range of 1.06 to 1.18, while its 52-week range spans from 0.56 to 2.11.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.